Another critical issue is the potential for antigen escape mechanisms, such as loss of CLL-1 expression or downregulation, which could undermine the durability of these therapies and contribute to relapse, a major obstacle in AML treatment. This evidence concerns the gene CLEC12A and acute myeloid leukemia.